ResMed Inc. Unveils Stewardship Presentation Highlighting Fiscal 2025 Achievements and 2030 Strategy

Reuters
2025/09/13
ResMed Inc. Unveils Stewardship Presentation Highlighting Fiscal 2025 Achievements and 2030 <a href="https://laohu8.com/S/MSTR">Strategy</a>

ResMed Inc. recently shared highlights from its fiscal 2025 performance, focusing on its strategy for 2030. The company reported a revenue of $5.1 billion with an operating margin of 33% GAAP and 34% Non-GAAP. ResMed serves over 140 countries and employs more than 10,000 people. Their revenue by business is divided among Devices, Masks & Other, and Residential Care Software $(RCS)$, while regional revenue is primarily from the U.S., Canada, and Latin America. The company's focus areas include enhancing patient experience through innovative solutions for Sleep Apnea, improving outcomes for COPD patients, and providing residential care software solutions. ResMed aims to empower 500 million lives by 2030 and has already impacted over 154 million lives with its digital health products and cloud-based software solutions in the past year. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ResMed Inc. published the original content used to generate this news brief on September 12, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10